Anastrozole Plus Trastuzumab Prolongs Progression-Free Survival in Postmenopausal Patients with HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Review of the TAnDEM Study

Breast Diseases

Volumn 18, Issue 3, 2007, Pages 236-237

  Basi, Sanraj K ^a   Mackey, John R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548461528     PISSN: 1043321X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-321X(07)80292-X     Document Type: Article

References (10)

1. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
2. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
3. Brufsky A., Lembersky B., Schiffman K., et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6 (2005) 247-252
4. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8 (2001) 191-195
5. Dowsett M., Harper-Wynne C., Boeddinghaus I., et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61 (2001) 8452-8458
6. Lipton A., Ali S., Leitzel K., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20 (2002) 1467-1472
7. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11 (2005) 4741-4748
8. Jones A. Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: What can be expected and why?. Ann Oncol 14 (2003) 1697-1704
9. Dowsett M., Allred D., et al., on Behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial (abstract 48). Presented at the 2006 San Antonio Breast Cancer Symposium. Available at http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_406 Accessed May 7, 2007.
10. Arpino G., Gutierrez C., Weiss H., et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99 (2007) 694-705